Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759182 | 0.90 | CHRM2 (0.50) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL6029821 | 0.82 | GLS (0.45) | GLSCASP3CA1CA2CA4 | |
| Taltrimide SCHEMBL347001 | 0.82 | NPSR1 (0.48) | GLSCASP3CA1CA2CA4 | |
| Taltrimide SCHEMBL29866257 | 0.82 | NPSR1 (0.48) | GLSCASP3CA1CA2CA4 | |
| SCHEMBL3759156 | 0.81 | CASP3 (0.49) | GLSCASP3CA1CA2CA4 | |
| SCHEMBL11014716 | 0.81 | KDM4E (0.49) | GLSCA9MEN1KMT2APOLB | |
| SCHEMBL1306411 | 0.80 | GLS (0.53) | GLSCASP3CA1CA2CA4 | |
| SCHEMBL10897112 | 0.80 | GLS (0.46) | GLSCASP3CA1CA2CA4 | |
| SCHEMBL18605556 | 0.80 | GLS (0.42) | GLSCASP3CA1CA2CA4 | |
| SCHEMBL20111946 | 0.79 | CASP3 (0.47) | GLSCASP3CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-2238119-B1 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
| WO-2007084319-A2 | DIARYL PIPERIDINES AS CB1 MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | RXFP3, RXFP1, NR1I3 | GLS 1319/4885CASP3 1238/4885CA1 1433/4885 |
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GLS 40/4885CASP3 3381/4885CA1 4537/4885 |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | GLS 2188/4885CASP3 468/4885CA1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.